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Abstract
Lynch Syndrome is characterised by the development of colorectal, endometrial and other cancers, often at a young 
age. It is caused by constitutional mutations of DNA mismatch repair genes and cancers that arise in this setting 
are mismatch repair deficient, as demonstrated by loss of the relevant mismatch repair protein and microsatellite 
instability. In theory, universal screening of all index colorectal cancers for mismatch repair deficient should identify 
individuals who are at higher than population risk of carrying a constitutional mutation in the mismatch repair genes. 
A health economic evaluation in the UK found that this type of screening strategy applied to individuals under the  
age of 51 years was highly cost effective. In Australia, some centres routinely test all colorectal cancers for 
mismatch repair deficient, however there is currently no systematic national approach to screening. Given the cost 
effectiveness of universal screening is dependent on uptake of constitutional testing by the index case and their 
relatives, we suggest that research into the determinants and barriers to uptake of constitutional testing is a high 
priority. Further, given that the health care context can influence the assessment of cost-effectiveness, we propose 
that the UK economic evaluation also needs to be undertaken in an Australian context.
Lynch Syndrome (LS) is a familial cancer syndrome which 
predisposes to colorectal cancer (CRC), endometrial and 
other cancers, such as gastric and ovarian cancer. It is 
caused by constitutional mutations in the DNA mismatch 
repair (MMR) genes MSH2, MLH1, MSH6 and PMS2. 
Rarely, some cases of LS are caused by constitutional 
methylation of the promoter of MLH1 or MSH2 rather 
than a constitutional sequence change.1 Irrespective of 
mechanism, the normal cells of an individual with LS 
have proficient DNA repair despite containing a mutated 
allele (copy) of one of the mismatch repair genes. Once 
the remaining normal allele is mutated or lost, the cells 
accumulate a large numbers of mutations. It is unclear 
whether the increased mutation rate is, in itself, the driver 
to carcinogenesis, or whether this is a paraphenomenon 
and the driver is a reduction in apoptosis caused by an 
uncoupling of cell cycle control from recognition of DNA 
damage.2,3 
The average age of onset of CRC in LS is about 40 years, 
but cases of teenage cancer have been described. While 
some individuals never develop any tumours, many patients 
develop more than one cancer, some many more. Previous 
studies overestimated the cumulative risk of cancer in 
individuals with LS, reporting cumulative colorectal cancer 
risks of 80%. Recent studies have estimated lower cancer 
risks and have also shown that cancer risk and type of 
cancer depends on which of the four genes is mutated. 
For instance, Bonadona et al estimated cumulative risks of 
CRC by age 70 years of around 40% for MLH1 and MSH2 
mutation carriers, and 12% for MSH6 carriers.4 This study 
also showed that the risks of endometrial or ovarian cancer 
do not significantly increase until after the age of 40 years.
Identifying individuals with LS is important, since 
colonoscopic surveillance for both index cases and at-risk 
relatives reduces mortality from colorectal cancer. Biennial 
surveillance colonoscopy for LS patients is recommended 
because CRCs in LS appear to develop much more quickly 
than those in the general population.5-7 The estimates of 
population prevalence of LS have steadily risen, in part 
because of programs for universal screening of incident 
cancers for the hallmarks of LS. Currently, it appears that 
~1:1000 individuals have mutations in one of the four 
genes, giving a total population prevalence of ~1:250, thus 
accounting for approximately 2.8% of all CRCs.8
Tumour testing for LS
LS tumours are mismatch repair deficient (MMRD) and 
display microsatellite instability (MSI) and loss of the 
relevant mismatch repair (MMR) protein. The value of 
using MSI testing as a screening test for LS tumours is 
limited by the fact that 15% of sporadic CRC and some 
other cancers also display MSI as a consequence of 
somatic inactivation of the MLH1 gene. Another limitation 
of MSI testing is that the panel of MSI markers has been 
developed for colon cancers, and the testing is less 
sensitive when applied to endometrial and other cancers. 
Finally, the standard MSI markers often do not identify 
MMRD tumours, which arise in the context of an inherited 
mutation in MSH6 or PMS2.9
The observation that a specific somatic mutation of BRAF, 
known as V600E, is not found in LS-associated colon 
cancers, but is found in a majority of sporadic colon 
cancers with loss of MMR, has now provided the means 
for restricting constitutional testing to those individuals 
with a high likelihood of LS.10,11
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Expression of MMR proteins in tumours can be assessed 
by immunohistochemistry (IHC) and it is gene specific, 
however it is not a functional test, so expression of 
an MMR protein does not necessarily equate to MMR 
proficiency.12 Also, as mentioned above, the most frequent 
cause of loss of MMR protein staining in CRC is somatic 
(acquired) methylation of the MLH1 gene promoter. Both 
MSI and MMR IHC testing are included in some programs 
such as the UK National External Quality Assurance 
Service program.13,14 As with all tests, they have finite 
sensitivity and specificity, and there is no single test which 
will indicate LS with complete accuracy.
Surveillance and treatment for LS-affected 
individuals
Biennial colonoscopy from around the age of 25 years 
is the mainstay of LS surveillance and treatment.6,7 This 
allows identification and removal of premalignant lesions, 
and downstaging of cancers. However, it is acknowledged 
that even in the best hands, CRC mortality in LS can only 
be reduced by about half. There are no proven forms 
of effective surveillance for any other LS-associated 
cancers.6,7 For this reason, total abdominal hysterectomy 
and bilateral salpingooophorectomy is recommended 
after childbearing is completed, or from age 40 years, to 
reduce the risk of gynecological cancers.6,15 Nowadays, 
some surgeons recommend a total colectomy rather than 
a hemicolectomy as the preferred option for a LS patient 
with CRC. The rationale for the more extensive surgery 
relates to the high risk of cancer in residual colon and the 
reports of comparable quality of life following either type 
of surgery.16 
Two other approaches to cancer prophylaxis for LS are 
on the horizon. Firstly, in one major placebo-controlled 
double-blind trial, daily aspirin reduced the relative risk 
of CRC by 37%.17 In this study, the frequency and 
magnitude of side-effects was not high, in part because 
of the relatively young age of the participants. Given the 
high dose of aspirin (600mg) used in the CAPP2 study, 
a further dose determination trial (CaPP3) is planned. A 
second approach to cancer prophylaxis is currently being 
tested in a phase I/IIa vaccine trial of MicOryx, a vaccine 
directed at the specific abnormal proteins caused by loss 
on MMR in tumours with MSI.18-20
Current identification of LS
The Amsterdam Criteria were originally developed as 
a research tool to find the gene/s responsible for LS, 
rather than a clinical diagnostic aid in identifying such 
families.21 With successful identification of the MMR 
genes and improved understanding of LS, the Amsterdam 
Criteria were subsequently modified in recognition that 
endometrial cancer was a major LS associated tumour. 
However, the custom and practice became established 
that LS was initially diagnosed by family history, and 
tumour testing was an aid once a putative family had 
been identified. Subsequently, much time and effort has 
gone into models which can be used in clinical practice 
to predict which families have a greater chance of having 
a LS gene mutation, but the fact remains that diagnostic 
laboratories only find mutations in about 10-15% of cases 
referred to them.5
Subsequently, as LS tumour testing came into routine 
practice, it was realised that incident tumours could be 
tested without a requirement for a family history, including 
cases of young-onset, multiple or co-occurrence e.g. 
colorectal and endometrial cancer in the same individual.22 
Thus, at an international meeting in Bethesda in 1996, 
criteria were drawn up to aid in selection of tumours for 
LS testing, the so-called Bethesda Guidelines.23 As the 
variety of LS tumour types became apparent, so these 
were revised.24 Although the Bethesda Guidelines in 
their various forms do somewhat improve the specificity 
of LS identification, they are not sensitive. It has also 
been recognised that the criteria vary widely in their 
performance depending on the underlying gene.9,10 
Additionally, it has been found that not only do healthcare 
professionals rarely ask about a family history of cancer, 
they struggle with recognising LS and referring cases to 
clinical genetics.25,26
Furthermore, individuals who have de novo mutations or 
are adopted have little, if any hope of being identified at 
risk of LS in a system based on family histories. 
Universal screening of tumours for LS: 
international overview and cost-effectiveness
In response to the realisation that ascertaining LS by means 
of family histories had distinct limitations, the International 
Society for Gastrointestinal Hereditary Tumours produced 
a position statement on the identification of LS in Europe, 
in which systematic testing of LS-associated tumours 
was proposed. Simultaneously, a number of countries 
were endeavouring to institute such programs, either 
nationwide (notably Denmark) or in individual regions 
(Australia).5,27 
In  the UK, the Peninsula Technology Assessment Group 
(PenTAG),28 was contracted by the National Health Service 
National Institute of Health Research to undertake a health 
technology assessment on the diagnostic utility and cost-
effectiveness of genetic testing for LS in index cases of 
CRC under the age of 50 years of age.29 The PenTAG 
group built an economic model applicable to the National 
Health Service system. The model incorporated all test 
performance characteristics and costs, a full range of 
health (e.g. clinical genetics, oncology, surgery) and social 
care costs. Six different combinations of tumour tests 
(immunohistochemistry, MSI and/or BRAF) were evaluated 
and all were evaluated in comparison with no intervention. 
Also evaluated was the benefit of taking a family history 
and acting upon it, if it fulfilled the Amsterdam Criteria, and 
simply testing for constitutional mutations without tumour 
testing. The PenTAG model showed that all colorectal 
tumour testing-based strategies up to age 50 years offered 
the National Health Service good value for money versus 
no testing, with all incremental cost-effectiveness ratios 
below the National Institute for Health and Care Excellence 
threshold of <£20k(AU$36k) per quality adjusted life year 
(QALY) gained. The model predicts an expected average 
gain in longevity of 1.3-1.7 years for probands, and 1.1-
1.4 years for relatives. Moreover, cost-effectiveness was 
positive even if only the proband was identified with LS, 
albeit that identifying relatives, up to a point, is more cost-
effective. Interestingly, family history as a ‘test’ is more 
cost-effective than doing nothing, but not as cost-effective 
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as tumour testing, and simply sequencing all probands 
was also found to be cost-effective, although less so than 
tumour testing strategies. Furthermore, the model shows 
that it would still be cost-effective to test all tumours 
up to age 70, with incremental cost-effectiveness ratios 
<£20k(AU$36k)/QALY.
While tumour testing strategies which include MSI followed 
by BRAF testing appeared to give the best incremental 
net health benefit, all six tumour testing strategies are 
predicted to be effective and cost-effective. Thus there 
is little to choose between the available options and 
no justification to change current practices of universal 
screening for LS through tumour testing. A sensitivity 
analysis conducted as part of the modelling showed 
that the following factors had a substantial impact on 
cost-effectiveness: CRC incidence for individuals with 
LS; the mean number of relatives per proband (0 – 12; 
base = 5); the effectiveness of colonoscopy in preventing 
metachronous CRC; the cost of colonoscopy; and the 
psychological disutility associated with prophylactic 
total abdominal hysterectomy and bilateral salpingo-
oopherectomy disutility. Thus, the model usefully predicts 
areas requiring careful attention and further exploration.
Implementation of LS screening
Implementation of a LS screening program should 
necessarily fulfill the requirements for any screening 
program, including that there should be: a detectable 
disease marker; a simple, safe, precise and validated test; 
and an effective treatment with evidence of early treatment 
leading to better outcomes than delayed treatment. Value 
for money is also an important consideration, specifically 
the opportunity cost of the screening program (including 
testing, diagnosis and treatment, administration, training 
and quality assurance) should be economically balanced 
in relation to expenditure on medical care as a whole. 
Moreover, assessment against these criteria should 
have regard to evidence from cost benefit and/or cost 
effectiveness analyses and have regard to the effective 
use of available resources.30 In addition, there should be a 
plan for managing and monitoring the screening program 
and an agreed set of quality assurance standards, from 
which no doubt, the experience of other countries who 
have successfully implemented such programs will be 
germane.13,14 
Given that universal screening for LS theoretically satisfies 
the requirements for adoption into routine practice, 
it is important to consider the possible barriers to 
implementation. One barrier is the behavior and 
circumstances of clinicians and patients. In one study 
of population-based universal screening for LS, over half 
of the individuals identified did not take up constitutional 
testing or refused to be informed of their results. As a 
consequence, one third of LS cases were missed.31 
Another barrier is the capacity of clinical genetics and 
thence to colonoscopic surveillance services to accept 
new referrals. To accommodate the additional LS patients, 
it may be necessary to make changes elsewhere in the 
system, for example changing the approach to surveillance 
for those at moderately increased risk of CRC.32,33 
There are concerns that implementation of universal 
tumour testing amounts to genetic testing without consent. 
However, the situation is analogous to one where patients 
with polyposis are able to be diagnosed on sight and they 
and their relatives benefit from life-saving prophylaxis. 
Should those with LS be denied such a diagnosis 
simply because the tests they warrant are microscopic 
or molecular?  In effect, their cancers are unanswered 
referral letters. We require LS families to recognise they 
have a family history of a complex disorder, and we require 
doctors to be similarly skilled, but the evidence shows 
that such a pathway amounts to an unfair obstruction to 
a diagnosis which may save lives. In any event, such a 
testing program does not force a diagnosis of LS on an 
individual – reporting pathologists merely need to say in 
their report: “Testing shows that this cancer may be due 
to an inherited syndrome. Referral of the patient to clinical 
genetics is strongly indicated.”
Current status of universal tumour screening 
for LS in Australia
There is currently no consistent national approach to 
testing for LS in Australia. Although immunohistochemistry 
in tumour samples is rebatable by Medicare,34,35 molecular 
MSI and BRAF mutation testing in CRC is not (although 
testing for BRAF mutation status is approved for other 
indications).36 Genetic testing for constitutional mutations 
in MLH1, MSH2, MSH6 and PMS2 is also not Medicare-
reimbursed, although the State Health Departments 
in Victoria and Western Australia fund these tests.37 
However, two Australian LS testing experiences have 
been reported.27,38,39 In an evaluation of routine screening 
of incident CRC in South Eastern Sydney,27 participating 
cases with MMRD tumours were triaged into low- and 
high-likelihood LS cases based on IHC and BRAF 
mutation testing. Constitutional mutations were reported 
in ~7% (95%CI:3-18%). In WA, screening for LS has 
been in place since 2008 as part of the familial cancer 
program, which was established in several steps. A 2006 
evaluation of the cost-effectiveness of screening CRC 
tumours in WA found that offering genetic testing to first-
degree relatives, followed by intensive surveillance for 
cancer of the colorectal, endometrium, ovary, stomach 
and urinary tract, or prophylactic colorectal surgery, was 
cost-effective, incurring a net cost <$13,000 for a gain 
of eight CRC-free years.40 A pilot involving retrospective 
testing of CRC cases <60 years diagnosed from 2000-
2006 using MSI and molecular BRAF mutation testing 
was performed; high MSI tumours without BRAF mutation 
were further investigated using IHC, which led to the 
identification of previously unrecognised cases of LS.41 
Routine screening targeting incident CRC cases aged <60 
years has been established and a recent report concluded 
that the program has resulted in identification of two-thirds 
of the expected LS cases among CRC cases aged <60 
years in WA.38
Prior work suggests that uptake may be one of the major 
practical limitations of an LS screening process. In the 
South Eastern Sydney experience,~50% of MMRD CRC 
cases did not wish to proceed with further testing for 
LS.27 A systematic review reported that only 52% of first-
degree relatives of identified LS cases chose to receive 
genetic testing.42 However, once genetic testing has 
been performed, surveillance uptake may be relatively 
high.15,43,44 In an Australian study of confirmed LS carriers, 
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all had undergone colonoscopy by three years after 
testing and 69% of the female carriers had undergone 
gynaecological screening in the previous two years.43
Conclusion
Given the inconsistencies in current approaches to testing 
in Australia and the potential difficulties in achieving high 
uptake of testing if it were to be systematically offered, we 
suggest that research into the determinants and barriers to 
testing uptake is a high priority, as is performing a national 
assessment of the effectiveness and cost-effectiveness of 
systematic screening for LS in Australia.
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